Fig. 2From: SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targetedReduction of clonogenic potential of neoplastic MCs from 3 patients with MCL in the presence of increasing doses of bortezomib, ixazomib and carfilzomib. All the clonogenic survival rates are expressed as mean ± standard deviation of counts from two independent experimentsBack to article page